Possible Treatment for Niemann-Pick Disease Type C Performs Well in Clinical Trial
<a href="https://pixabay.com/users/DarkoStojanovic/">DarkoStojanovic</a> / Pixabay

Possible Treatment for Niemann-Pick Disease Type C Performs Well in Clinical Trial

According to a story from labiotech.eu, the biotechnology company Orphazyme has been developing an experimental therapy for Niemann-Pick disease type C. In a recent Phase 2/3 clinical trial, the investigational…

Continue Reading

CZI has Committed 64 Million Dollars to the Research of Neurodegenerative Disorders

Neurodegenerative disorders affect millions of people across the world. They include Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, and Alzheimer's disease, among others. For most neurodegenerative diagnoses, there are no effective treatments, no…

Continue Reading
ICYMI: Potential Treatment in the Works for Familial Amyotrophic Lateral Sclerosis
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay

ICYMI: Potential Treatment in the Works for Familial Amyotrophic Lateral Sclerosis

According to a story from telegram.com, a group of researchers from the University of Massachusetts medical school recently announced that they may have reached a major treatment breakthrough for genetically…

Continue Reading
This Company Just Endorsed New Patient Advocacy Guidelines
<a href="https://pixabay.com/users/mohamed_hassan/">mohamed_hassan</a> / Pixabay

This Company Just Endorsed New Patient Advocacy Guidelines

According to a story from globenewswire.com, the biopharmaceutical company Orphazyme has officially endorsed a set of guidelines that outline how rare disease patient advocacy organizations and drug companies should interact…

Continue Reading
Close Menu